United States · Markets & Finance · Yahoo Finance

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Published by Yahoo Finance · United States 10 h ago

BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced…

Read the full article on Yahoo Finance Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

Cointelegraph

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

Business Insider

'SNL' takes aim at Kevin O’Leary and his Utah data center: 'I'm going to make the future go away’

CoinDesk

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Share

Also worth reading

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

'SNL' takes aim at Kevin O’Leary and his Utah data center: 'I'm going to make the future go away’

Everyone wants SCOTUS to take up prediction markets: State of Crypto